Summary
5-FUra is a familiar member of a variety of clinically useful regimens. Examples include: Cytoxan-Adriamycin-5-FUra (CAP); Methotrexate-Prednisone-Vincristine-Cytoxan-5-FUra (the Cooper regimen); and CisDDPt-5-FUra. In addition to its clinical utility, over 20 different 5-FUra-combinations have been reported to be therapeutically synergistic in experimental systems (Table 1). In this report, we will attempt to evaluate the reasons behind the widespread utility of this agent in combination therapy and suggest future directions for research efforts.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Venditti JM, Goldin A: Drug synergism in antineoplastic chemotherapy. Adv Chemother 1:397–498, 1964
Carter SK: Planning combined therapy — The interaction of experimental and clinical studies. Cancer Chemother Rep 4:3–11, 1974
Corbett TH, Griswold Jr DP, Wolpert MK, Venditti JM, Schabel Jr FM: Design and evaluation of combination chemotherapy trials in experimental animal tumor systems. Cancer Treat Rep 63:799–801, 1979
Corbett TH, Roberts BJ, Trader MW, Laster Jr WR, Griswold Jr DP, Schabel Jr FM: Response of transplantable tumors of mice to anthracenedione derivatives alone and in combination with clinically useful agents. Cancer Treat Rep 66:1187–1200, 1982
Skipper HE: Combination therapy: Some concepts and results. Cancer Chemother Rep 4:137–145, 1974
Skipper H: The effects of chemotherapy on the kinetics of leukemic cell behavior. Cancer Res 25:1544–1550, 1965
Schabel Jr FM: Synergism and antagonism among antitumor agents from; pharmacological basis of cancer chemotherapy. The twenty-seventh annual symposium on fundamental cancer research, pp 595–623, 1975, The Williams and Wilkins Company, Baltimore, Maryland
Corbett TH, Leopold WR, Dykes DJ, Roberts BJ, Griswold Jr DP, Schabel Jr FM: Toxicity and anticancer activity of a new triazine antifolate (NSC 127755). Cancer Res 42:1701–1715, 1982
Corbett TH, Griswold Jr DP, Roberts BJ, Schabel Jr FM: Cytotoxic adjuvant therapy and the experimental model, Chapter 10. In: Stoll BA (ed), New Aspects of Breast Cancer. Vol. 4: Systemic Control of Breast Cancer, pp 204–243, London: William Heinemann Medical Books, Ltd., 1981
Corbett TH, Roberts BJ, Leopold WR, Peckham JC, Wilkoff LJ, Griswold Jr DP, Schabel Jr FM: Induction and chemotherapeutics response of two transplantable ductal adenocarcinomas of the pancreas in C57B1/6 mice. Cancer Res 44:717–726, 1984
Corbett TH, Valeriote FA, Baker LH: Is the P388 murine tumor no longer adequate as a drug discovery model? Invest New Drugs 5:3–20, 1987
Corbett TH, Griswold Jr DP, Roberts BJ, Peckham JC, Schabel Jr FM: Evaluation of single agents and combinations of chemotherapeutic agents in mouse colon carcinomas. Cancer 40:2660–2680, 1977
Corbett TH, Griswold Jr DP, Roberts BJ, Peckham JC, Schabel Jr FM: Biology and therapeutic response of a mouse mammary adenocarcinoma (16/C) and its potential as a model for surgical adjuvant chemotherapy. Cancer Treat Rep 62:1471–1499, 1978
Schabel Jr FM, Skipper HE, Trader MW, Laster WR, Griswold Jr DP, Corbett TH: Establishment of crossresistance profiles for new agents. Cancer Treat Rep 67:905–922, 1983. [Corrected tables to this article are published in Cancer Treat Rep 68:453–459, 1984
Peterson RH, O'Neil JA, Biedler JL: Some biochemical properties of Chinese hamster cells sensitive and resistant to actinomycin D. J Cell Biol 63:773, 1974
Bleyer WA, Frisby SA, Oliverio VT: Uptake and binding of vincristine by murine leukemia cells. Biochemical Pharmacol 24:633, 1975
Johnson RK, Chitnis MP, Embrey WM, Gregory EB: In vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388 leukemia. Cancer Treat Rep 62:1535, 1978
Kaye SB, Boden JA: Cross resistance between actinomycin-D, adriamycin, and vincristine in a murine solid tumor in vivo. Biochem Pharmacol 29:1081–1084, 1980
Bosmann HB: Mechanism of cellular drug resistance. Nature 233:566, 1971
Kessel D, Corbett TH: Correlations between anthracycline resistance, drug accumulation and membrane glycoprotein patterns in solid tumors of mice. Cancer Lett 28:187–193, 1985
Skipper HE, Hutchisson DJ, Schabel Jr FM, Schmidt LH, Golden A, Brockman RW, Venditti JM, Wodinsky I: A quick reference chart on cross resistance between anticancer agents. Cancer Chemotherapy Rep 56:493–498, 1972
Pazdur R, Redman BG, Corbett TH, Phillips M, Baker LH: Phase-I trial of spirohydantoin mustard (spiromustine/ NSC-172112) and evaluation of toxicity and schedule in a murine model. Cancer Res 47:4213–4217, 1987
Corbett TH, Bissery M, Wozniak A, Plowman J, Polin L, Tapazoglou E, Dieckman J, Valeriote F: Activity of flavone acetic acid (NSC-347512) against solid tumors of mice. Invest New Drugs 4:207–220, 1986
Leichman CG, Corbett TH, Leichman L: Improved treatment results in murine colon tumors treated with infusion 5-FU vs. Standard bolus schedule. Proc Am Assoc Cancer Res 26:355, 1985
Heidelberger C: Fluorinated pyrimidines and their nucleosides. In: Sartorelli AC, Johns DG (eds), Handbook of Experimental Pharmacology, XXXVIII/2: Antineoplastic and Immunospressive Agents, Part II, pp 193–231. Springer-Verlag Berlin. Heidelberg. New York, 1975
Vietti R, Eggerding F, Valeriote F: Combined effect of X radiation and 5-fluorouracil on survival of transplanted leukemia cells. J Natl Cancer Instit 47:865–870, 1971
Corbett TH: The use of a multiple-turn or-soft-agar-disk-diffusion-assay to detect agents with selective solid tumor activity. Symposium III: New approaches to the discovery of anticancer agents. (Abstr) Proc Am Assoc Cancer Res 29:533–534, 1988
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Corbett, T.H., Bissery, MC., Mucci-LoRusso, P. et al. 5-Fluorouracil containing combinations in murine tumor systems. Invest New Drugs 7, 37–49 (1989). https://doi.org/10.1007/BF00178190
Issue Date:
DOI: https://doi.org/10.1007/BF00178190